DeciBio Ventures flags pharma services sector push into AI-enabled clinical development in Q3 2026 roundup
XLV•DeciBio Ventures’ Q3 2026 roundup highlighted accelerating AI adoption in clinical development, including an ICON collaboration with Anthropic and several acquisitions. Samsung Biologics offered $1.8 billion for PolyPeptide, Tempus AI agreed to acquire Personalis, and Fortrea agreed to buy Worldwide’s early phase services unit for $45 million.
1. AI in clinical development
The roundup flagged accelerating AI adoption across clinical development platforms. ICON entered a multi-year collaboration with Anthropic to embed Claude into Orbis for trial operations, including site selection.
2. Deals and capacity
Samsung Biologics launched an all-cash tender offer of $1.8 billion for PolyPeptide, targeting peptide capacity tied to GLP-1 demand. Tempus AI agreed to acquire Personalis to add minimal residual disease testing, while Fortrea agreed to buy Worldwide’s early phase services unit for $45 million, expanding its capabilities through lab and clinic assets.
